Comparison of major studies performed in non-small cell lung cancer (NSCLC) to investigate the prognostic significance of ALDH1/ALDH1A1 and CD133
| Reference | Population | Number of patients | Specimen | Stem cell marker/s | Primary antibody | Cut-off point (%) | Positive cases (%) | Follow up in months | Main results | |
|---|---|---|---|---|---|---|---|---|---|---|
| Min | Median | |||||||||
| Jiang et al9 | Stage 1 NSCLC | 148 | TMA | ALDH1 | Rabbit polyclonal (Santa cruz) | >10 | 29 | NM | ALDH1 positive patients have worse OS (p=0.006) | |
| Salnikov et al32 | Stage I–III NSCLC | 81 | Whole section | CD133 | Rabbit polyclonal (Abcam) | Any* | 63 | NM | CD133 expression did not correlate with survival. | |
| Sullivan et al31 | All stages NSCLC | 282 | TMA | ALDH1A1 | Rabbit monoclonal (Abcam) | Median | 51 | NM | ALDH1A1 high expression was associated with poor survival (p=0.025) No association between ALDH3A1 and CD133 expression and survival | |
| ALDH3A1 | Santa Cruz | Median | 50 | |||||||
| CD133 | Mouse monoclonal (Miltenyi) | Any | 27 | |||||||
| Woo et al33 | Stage 1 ADC | 177 | Whole sections | CD133 | Mouse monoclonal (Miltenyi) | >17.5 | 45.8 | 1.1 | 35.9 | CD133 high expressers was associated with worse DFS (p=0.004) |
| Okudela et al34 | Stage 1 ADC | 177 | Whole sections | ALDH1 | Rabbit monoclonal (Abcam) | >85 | 20.3 | 1.1 | 35.9 | High expression of ALDH1, CD133 and CD44 was associated with worse DFS (p=0.036, 0.021, 0.023 respectively) |
| CD133 | Mouse monoclonal (Miltenyi) | >17.5 | 45.8 | |||||||
| Li et al35 | All stages NSCLC | 179 | TMA | ALDH1A1 | Rabbit monoclonal (Abcam) | Any | 45 | 6 | 49.2 | ALDH1A1 positive patients had shorter survival |
| Current study | Stage 1 NSCLC | 205 | Whole sections | ALDH1A1 | Rabbit monoclonal (Abcam) Mouse monoclonal (BD) | >10 | 69 | 18 | 60 | ALDH1A1 and CD133 overexpression is associated with shorter OS (p=0.017 and 0.039, respectively) |
| CD133 | Rabbit polyclonal (Abcam) Rabbit polyclonal (Bioss) | >5 | 50.7 | Patients expressing both ALDH1A1 and CD133 had worse survival (p=0.017) | ||||||
*Any=any positive staining was considered positive, regardless of percentage or intensity.
ADC, adenocarcinoma; ALDH1, aldehyde dehydrogenase 1; ALDH1A1, aldehyde dehydrogenase 1A1; DFS, disease-free survival; Min, minimum follow-up; NM, not mentioned; OS, overall survival; TMA, tissue microarray.